Table 1 |
|||||
| Epidemiological data and comorbidities of patients included in the study distributed by diagnostic category; [n (%)] except where indicated | |||||
| Total | Colonised | Aspergillosis | |||
| Probable | Proven | Probable + Proven | |||
| No. Patients | 245 | 106 | 125 | 14 | 139 |
| Age (mean ± SD) | 68.7 ± 15.2 | 69.1 ± 16.1 | 68.9 ± 14.6 | 64.1 ± 14.5 | 68.4 ± 14.6 |
| Males | 171 (69.8) | 67 (63.2) | 94 (75.2) | 10 (71.4) | 104 (74.8)a |
| Comorbiditiesb | |||||
| COPD | 173 (70.6) | 73 (68.9) | 91 (72.8) | 9 (64.3) | 100 (71.9) |
| Gold III + IVc | 111 (67.3) | 40 (57.2) | 66 (76.7)a | 5 (55.6) | 71 (74.7)a |
| Diabetes Mellitus II | 43 (17.6) | 19 (17.9) | 23 (18.4) | 1 (7.1) | 24 (17.3) |
| Congestive heart failure | 45 (18.4) | 13 (12.3) | 27 (21.6) | 5 (35.7)a | 32 (23.0)a |
| Malignancies | 38 (15.5) | 10 (9.4) | 27 (21.6)a | 1 (7.1) | 28 (20.1)a |
| Renal impairment | 24 (9.8) | 10 (9.4) | 12 (9.6) | 2 (14.3) | 14 (10.1) |
| Charlson (mean ± SD) | 2.61 ± 2.16 | 2.42 ± 2.03 | 2.81 ± 2.29 | 2.21 ± 1.76 | 2.75 ± 2.75 |
| APACHE (mean ± SD) | 13.16 ± 6.86 | 11.63 ± 6.12 | 14.13 ± 6.67a | 16.14 ± 10.90 | 14.33 ± 7.18a |
| ICU admission at any time during hospital stay | 58 (23.7) | 15 (14.2) | 36 (28.8)a | 7 (50.0)a | 43 (30.9)a |
ap ≤ 0.050 vs. colonised; bpresent in ≈ > 10% total patients; camong patients with available data (165 patients in total: 70 colonized, 86 probable and 9 proven).
Barberan et al. BMC Infectious Diseases 2012 12:295 doi:10.1186/1471-2334-12-295
